Listen on the go
CORRECT!
Next question
touchRESPIRATORY touchRESPIRATORY
Allergy

Dermot Ryan, IPCRG 2021: Allergen Immunotherapy in Primary Care

Copy Link
Published Online: May 26th 2021

TouchRESPIRATORY got the opportunity to catch up with Dr Dermot Ryan (Asthma UK Centre for Applied Research, The University of Edinburgh, Edinburgh, Scotland) around his presentation on ‘Respiratory Allergy: The Role of Immunotherapy in Primary Care.’ which was presented at The IPCRG 10th World Conference, 6-8 May, 2021.

Questions

  1. According to current IPCRG guidelines, for which patients is allergen immunotherapy recommended? (0:27)
  2. Could you give us a brief overview of the methods of allergen immunotherapy that are currently used in primary care? (2:27)
  3. What factors predict a successful response to allergen immunotherapy? (4:07)
  4. How do you expect the role of allergen immunotherapy in primary care to develop in the future? (5:08)

Disclosures: Dermot Ryan has nothing to disclose in relation to this video

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.

Filmed as a highlight of IPCRG 2021 (Virtual).

Share this Video
Related Videos In Allergy
Allergy, Asthma, Rhinosinusitis
Developed by Touch
Isaac Schmale, AAAAI 2023: Efficacy of dupilumab for nasal polyposis in patients with aspirin-exacerbated respiratory disease
Watch Time: 6 mins

Dupilumab is used to manage chronic rhinosinusitis with nasal polyposis, however there is limited data regarding its use in patients with aspirin-exacerbated respiratory disease (AERD). touchRESPIRATORY caught up with Dr Isaac Schmale (University of Rochester Medical Center, Rochester, NY, USA) around the aims, eligibility, methodology and findings of his study investigating the real-world outcomes of […]

Allergy, Asthma, Rhinosinusitis
Developed by Touch
Isaac Schmale, AAAAI 2023: Signs and symptoms of aspirin-exacerbated respiratory disease and its treatment paradigm
Watch Time: 4 mins

touchRESPIRATORY were delighted to speak with Dr Isaac Schmale (University of Rochester Medical Center, Rochester, NY, USA) around the signs and symptoms of aspirin-exacerbated respiratory disease (AERD), the incidence of AERD in people with asthma, the current treatment paradigm for AERD and the unmet needs in its treatment. The abstract ‘Real-world Outcomes of Dupilumab Therapy […]

Allergy
Developed by Touch
Ozge Can Bostan, EAACI 2022: Low Dose Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis
Watch Time: 4 mins

Mepolizumab is currently approved for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) at a dose of 300mg. touchRESPIRATORY caught up with Dr. Ozge Can Bostan (Hacettepe University School of Medicine, Ankara, Turkey) to discuss the 1 year findings from her study investigating the sinonasal and respiratory outcomes of a low dose of mepolizumab (100 […]

Trending In Allergy:

Isaac Schmale, AAAAI 2023: Efficacy of dupilumab for nasal polyposis in patients with aspirin-exacerbated respiratory disease
Allergy, Asthma, Rhinosinusitis
    • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72